• Explore /
  • Poster
  • / Efficacy and immune modulation by BXCL701 a dipeptidyl peptidase inhibitor, NKTR-214 a CD122-biased immune agonist with PD1 blockade in murine pancreatic tumors.

Efficacy and immune modulation by BXCL701 a dipeptidyl peptidase inhibitor, NKTR-214 a CD122-biased immune agonist with PD1 blockade in murine pancreatic tumors.

Abstract Poster

Authors

null

Luca Rastelli

bioxcel therapeutics, Branford, CT

Luca Rastelli , Snigdha Gupta , Zeenia Jagga , Deborah H. Charych , Jonathan Zalevsky

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Immune Checkpoint Inhibitors

Citation

J Clin Oncol 36, 2018 (suppl; abstr 3085)

DOI

10.1200/JCO.2018.36.15_suppl.3085

Abstract #

3085

Poster Bd #

299

Abstract Disclosures

Similar Posters

Poster

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Activity of CBT-501, a novel humanized anti-PD-1 antibody, in a humanized genetically engineered mouse model of colon carcinoma.

Activity of CBT-501, a novel humanized anti-PD-1 antibody, in a humanized genetically engineered mouse model of colon carcinoma.

First Author: Qing Zhou

First Author: Xing Zhao

First Author: Mark Selby

First Author: Ahmad A. Tarhini